PMGC Shares Soar After Subsidiary Amends License Agreement

Dow Jones

Mar 28

By Katherine Hamilton

Shares of PMGC Holdings climbed after its NorthStrive Biosciences subsidiary amended a license agreement to allow for an expedited clinical development process.

The stock gained 87% to $3.13 in after-hours trading Friday. The shares touched a three-year low $1.62 in market trading before closing down 11% at $1.67.

NorthStrive amended its agreement with MOA Life Plus, a Korean biotechnology company, for the human clinical development programs EL-32 and EL-22.

The amendment allows NorthStrive to potentially skip a Phase 1 clinical trial in the program before moving on to a Phase 2 trial.

NorthStrive would be excused from satisfying its development milestone for Phase 1, as long as it provided MOA written documentation showing scientific support for a Phase 2 trial.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

March 27, 2026 17:42 ET (21:42 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2622805909"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622805909\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622805909?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-28 05:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622805909","market":"nz","top_or_hot":-1,"title":"PMGC Shares Soar After Subsidiary Amends License Agreement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ELAB\">PMGC Holdings</a> climbed after its NorthStrive Biosciences subsidiary amended a license agreement to allow for an expedited clinical development process. \n</p>\n<p>\n  The stock gained 87% to $3.13 in after-hours trading Friday. The shares touched a three-year low $1.62 in market trading before closing down 11% at $1.67. \n</p>\n<p>\n  NorthStrive amended its agreement with MOA Life Plus, a Korean biotechnology company, for the human clinical development programs EL-32 and EL-22. \n</p>\n<p>\n  The amendment allows NorthStrive to potentially skip a Phase 1 clinical trial in the program before moving on to a Phase 2 trial. \n</p>\n<p>\n  NorthStrive would be excused from satisfying its development milestone for Phase 1, as long as it provided MOA written documentation showing scientific support for a Phase 2 trial. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 27, 2026 17:42 ET (21:42 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PMGC Shares Soar After Subsidiary Amends License Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPMGC Shares Soar After Subsidiary Amends License Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-28 05:42</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ELAB\">PMGC Holdings</a> climbed after its NorthStrive Biosciences subsidiary amended a license agreement to allow for an expedited clinical development process. \n</p>\n<p>\n  The stock gained 87% to $3.13 in after-hours trading Friday. The shares touched a three-year low $1.62 in market trading before closing down 11% at $1.67. \n</p>\n<p>\n  NorthStrive amended its agreement with MOA Life Plus, a Korean biotechnology company, for the human clinical development programs EL-32 and EL-22. \n</p>\n<p>\n  The amendment allows NorthStrive to potentially skip a Phase 1 clinical trial in the program before moving on to a Phase 2 trial. \n</p>\n<p>\n  NorthStrive would be excused from satisfying its development milestone for Phase 1, as long as it provided MOA written documentation showing scientific support for a Phase 2 trial. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 27, 2026 17:42 ET (21:42 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4183","symbol_name":"个人用品","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2622805909","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622805909","pubTimestamp":1774647720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of PMGC Holdings climbed after its NorthStrive Biosciences subsidiary amended a license agreement to allow for an expedited clinical development process.The stock gained 87% to $3.13 in after-hours trading Friday. The shares touched a three-year low $1.62 in market trading before closing down 11% at $1.67.NorthStrive amended its agreement with MOA Life Plus, a Korean biotechnology company, for the human clinical development programs EL-32 and EL-22.The amendment allows NorthStrive to potentially skip a Phase 1 clinical trial in the program before moving on to a Phase 2 trial.NorthStrive would be excused from satisfying its development milestone for Phase 1, as long as it provided MOA written documentation showing scientific support for a Phase 2 trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4183":"个人用品","ELAB":"PMGC Holdings"},"translate_title":"子公司修改许可协议后PMGC股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELAB":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Shares of PMGC Holdings climbed after its NorthStrive Biosciences subsidiary amended a license agreement to allow for an expedited clinical development process. \n\n\n  The stock gained 87% to $3.13 in after-hours trading Friday. The shares touched a three-year low $1.62 in market trading before closing down 11% at $1.67. \n\n\n  NorthStrive amended its agreement with MOA Life Plus, a Korean biotechnology company, for the human clinical development programs EL-32 and EL-22. \n\n\n  The amendment allows NorthStrive to potentially skip a Phase 1 clinical trial in the program before moving on to a Phase 2 trial. \n\n\n  NorthStrive would be excused from satisfying its development milestone for Phase 1, as long as it provided MOA written documentation showing scientific support for a Phase 2 trial. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2026 17:42 ET (21:42 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}